EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported E.P.S. of $-0.33 for its fourth fiscal quarter (ending December 31) versus $-1.16 for the same period a year ago. For the latest four quarters through December 31, E.P.S. were $-1.82 compared to $-2.74 a year ago.
Recent Price Action
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock closed at $25.31 on 3/7/24 after a modest decline of -1.7%. However, this decline was accompanied by below average trading volume at 82% of normal. The stock has declined -8.6% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, EYPT is expected to be Value Creation neutral.
EyePoint Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. EyePoint Pharmaceuticals has a very low Appreciation Score of 2 but a very high Power Rating of 99, producing the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment